MAI CDMO

 A delayed product launch can cost months of revenue and years of trust. In animal health, the reason behind those delays is often the same. Regulatory missteps. Many companies discover too late that manufacturing quality alone is not enough. Regulatory experience makes or breaks a project when selecting a  veterinary CDMO .   This blog explains the importance of regulatory expertise, its effect on compliance and timeline, and the things to consider prior to signing the contract.   The Regulatory Reality of Veterinary Drug Manufacturing Veterinary drugs are in an ambiguous territory. They will not be regulated in a strict manner like human drugs, but the expectations are high. Food production authorities require evidence of safety, quality and consistency, particularly in food-producing animals.   Each region applies different rules.   · The FDA Center for Veterinary Medicine in the United States · The European Medicines Agency in the EU...

One of the founders of the biotech had a bitter experience. The science was solid. The funding was there. The clinical plan made sense. The bottleneck, nevertheless, was in manufacturing. The chosen partner could not scale since the time constraints were shorter, and the program lost nearly one year. That experience is not rare. In pharmaceutical contract manufacturing , the right partner can move a program forward quietly. The wrong one can stop it cold.   This blog breaks down the key capabilities to look for in a Contract Manufacturing Organization , with a practical lens shaped by real industry outcomes. Risk, compliance and timelines are involved; it would always be a matter of what matters.   Proven Regulatory Compliance and Quality Systems Regulatory readiness is not optional. It is the foundation.   A capable CMO operates with robust GMP systems , clear documentation practices, and a history of successful inspections. Look beyond certifications on a website. Ask a...

 Cell line development used to be the quiet part of biologics manufacturing. It was well known that it made or broke a program, yet few discussed the extent to which it could go. Today, that has changed. The Biopharmaceutical CDMOs will offer much more than just capacity, but smarter science with shorter schedules, higher cost pressure, and intricate molecules.   A single poorly performing cell line can add months to development and millions to cost. On the other hand, a highly optimized cell line that has a vigorous process can increase the yields, consistency, and scale to a great extent. That is where the contemporary biopharmaceutical contract manufacturing comes in.   This blog breaks down how experienced CDMOs approach cell line development and process optimization, and what sponsors can learn from it.   Why Cell Line Development Still Defines Biologics Success Biologics manufacturing begins long before the first GMP batch. The choices taken at...

 Since its launch in September, MAI CDMO has been making waves as the top collaborative Contract Manufacturing platform in Spain. In just a few months, the platform has achieved remarkable milestones, underscoring its growing impact on the pharmaceutical and biotechnology industries. https://mai-cdmo.blogspot.com/2025/04/mai-cdmo-leading-way-in-collaborative.html

 In today’s rapidly evolving pharmaceutical landscape, CDMO services (Contract Development and Manufacturing Organizations) are becoming increasingly vital. As the demand for advanced therapies grows, companies are looking for expert partners who can help accelerate the journey from concept to market. https://mai-cdmo.blogspot.com/2025/06/why-cdmo-services-are-transforming.html

 Antibody Drug Conjugates have become one of the emerging divisions in oncology pipelines. Recent industry tracking suggests that over 200 ADC candidates are actively being developed in the world today, with complexity escalating at every stage. Science is no longer the bottleneck, but manufacturing is.   This blog breaks down how advanced bioconjugation techniques are shaping modern adc cdmo  production, why sponsor companies rely heavily on specialized partners and what practical lessons emerge when scaling these systems for clinical and commercial supply.   Why Bioconjugation Matters More Than Ever ADC performance depends on three elements working together: the antibody, the linker and the payload. It is in bioconjugation that these parts are incorporated as an entity of functionality. Even a minor variation in this procedure may change its efficacy, toxicity, or stability.   Early ADC programs relied on random conjugation methods. That approach w...